Cellivery Announces New Drug for Severe Obesity and Diabetes Treatment at American Diabetes Association Conference

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 11th that two related studies on the novel drug CP-deltaSOCS3 for the treatment of severe obesity and type 2 diabetes have been selected as final topic presenters at the American Diabetes Association (hereinafter ADA).

ADA is an annual academic conference related to obesity and diabetes. This year, it is scheduled to be held for five days starting from the 12th. Due to the novel coronavirus infection (COVID-19), the conference will be held online. The topic presentation abstracts will be released the day before in Korean time, and the presentation materials will be made public worldwide on the 14th.

The content Cellivery will present at ADA2020 includes two studies: the therapeutic efficacy of CP-deltaSOCS3 for severe obesity through regulation of appetite suppression signaling pathways, and the therapeutic efficacy of CP-deltaSOCS3 for type 2 diabetes by overcoming insulin resistance.

Currently, obesity treatments mainly consist of appetite suppressants that increase the action of neurotransmitters in the brain to reduce hunger or increase satiety, and lipase inhibitors that prevent fat absorption and promote excretion to reduce body weight. However, earlier this year, the U.S. Food and Drug Administration (FDA) withdrew Belviq, a representative psychotropic drug, from the market due to the potential risk of cancer. Therefore, overcoming side effects such as severe headaches, depression, dizziness, and diarrhea associated with current obesity treatments is essential for new drugs to enter the obesity treatment market.

Daewoong Cho, CEO of Cellivery, stated, “Compared to the weight loss effects of existing psychotropic drugs acting on the central nervous system (CNS), CP-deltaSOCS3, a recombinant protein based on human protein, shows 15-25% weight loss, 54% reduction in abdominal fat, and 29% decrease in food intake after two weeks of administration.” He added, “Unlike existing psychotropic drugs, CP-deltaSOCS3 directly crosses the blood-brain barrier (BBB) of obese patients whose leptin appetite suppression is lost, allowing them to properly regulate their appetite and thus demonstrating weight loss efficacy.” He further noted, “It is expected to be developed as a safe obesity treatment drug with little or no side effects compared to psychotropic treatments.”

He explained, “CP-deltaSOCS3 not only has therapeutic efficacy for severe obesity but also shows 67% blood glucose reduction and 74% fatty liver treatment efficacy in type 2 diabetes, demonstrating strong therapeutic effects for both severe obesity and type 2 diabetes.”

Currently, CP-deltaSOCS3 is undergoing non-clinical trials including process development, mass production, and encapsulation at Aldevron in the U.S. and Lonza in Scotland. Last year, intellectual property (IP) necessary for licensing out (L/O) was secured through U.S. patent registration.

This content was produced with the assistance of AI translation services.